Notified body consolidation is likely to continue at a heavy pace over the next few years to the extent that only10 notified bodies or so will be operating in the medtech sector in five or so years time. That is the radical view of Martin de Bruin , ...

Are commercial and regulatory pressures becoming so tough that the smaller notified bodies are likely to be squeezed out of the medtech market? Amanda Maxwell reflects on recent developments and talks to BSI’s David Ford and four of his executives ...

It is not yet apparent what the next game-changing technology in the cardiovascular market will be, says Edwards Lifesciences ’ CEO Michael Mussallem. “Currently people are projecting moderate growth for the market. What I would suggest is ...

Norway has recently topped the United Nations human development index for 2009, making it the most “developed” country in the world. Surely this provides a background for strong medtech innovation? Joseph Harvey travelled to Oslo to meet with a ...

The annual BioPartnering Europe conference in London, UK, presents a networking opportunity for biotech and lifesciences firms both large and small. Joseph Harvey attended the event earlier this month to meet two young European companies that have ...

At a recent healthcare conference that he organised at Oslo’s Holmenfjord Hotel, Steven Burrill, CEO of lifesciences investment bank Burrill & Company, told Clinica that he believes Norway could become “a real leader” in medtech innovation in the ...

Norway is likely to be at the cutting edge of the shift towards predictive, personalised medicine, according to Steven Burrill. The CEO of life sciences investment firm Burrill & Company and personalised health "guru" said that the country’s HUNT ...